Next Science Limited announced that it has received a section 510(k) clearance from the Food and Drug Administration (FDA) for the sale of XPERIENCE No Rinse Antimicrobial Solution as a medical device in the United States. Sales of XPERIENCE in the US will commence immediately. XPERIENCE enters the market as a single step application where the residual solution remains in the surgical site after closure and continues to help defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections. XPERIENCE is designed for use in virtually every open surgery case, with the initial focus on: Shoulder, Hip, Knee, Trauma, and Podiatry. Next Science’s initial sales focus will be the US orthopaedic market of 5.3M surgeries per year in 20104, a market opportunity of over $1 billion per annum. The potential global market for XPERIENCE is greater than $15 billion per annum. Key clinical trials to provide additional evidence for Next Science to drive widespread adoption in the surgical community are commencing. XPERIENCE will be sold in the US through a third-party distribution network of over 300 commission agents managed by Next Science. Next Science’s sales network provides coverage to service more than 90% of the US including the 15,000 Hospitals and Ambulatory Surgery Centres that carry out more than 100 million surgical procedures in the US annually.